echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The new coronavirus causes the patient's immune system to attack their own tissues or organs

    The new coronavirus causes the patient's immune system to attack their own tissues or organs

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    University of Birmingham study: The new coronavirus causes the immune system of patients to attack their own tissues or organs
    University of Birmingham Research: The new coronavirus causes the patient’s immune system to attack their own tissues or organs.


    Since the outbreak of the new crown epidemic, there are still many unanswered questions about the clinical manifestations of patients
    .


    Previous observations have found that COVID-19 is related to a variety of unexpected symptoms, including Guillain-Barré syndrome and myocardial pericarditis, whether during treatment after diagnosis or several months after discharge


    It is not fully understood what causes these symptoms, but scientists have proposed a possibility that the new coronavirus triggers an autoimmune process that causes the immune system to be misled and attack itself instead
    .


    According to the official website of the University of Birmingham in the United Kingdom, a new study led by the school found that many COVID-19 patients have an immune response that attacks their own tissues or organs


    This study was recently published in Clinical & Experimental Immunology.
    The research team is from the University of Birmingham.
    The corresponding author is Alex G.
    Richter, a professor at the Institute of Immunology and Immunotherapy of the University of Birmingham and an honorary consultant in clinical immunology
    .


    According to the official website of the University of Birmingham, Richter has been leading a team of experts from the University of Birmingham to develop a SARS-CoV-2 antibody test


    This latest study investigated 84 patients with COVID-19, including COVID-19 patients who were in a severe phase at the time of testing, severe patients who were in recovery, and mild patients who did not need to be hospitalized
    .


    The results of the patient's study were compared with 32 control groups, who received intensive care for reasons other than COVID-19


    Autoantibody is an antibody (a protein) produced by the immune system.
    It directly targets one or more of the individual's own proteins and can cause autoimmune diseases
    .


    In some cases, infection can cause autoimmune diseases


    The new study completed by Richter and colleagues found that the number of autoantibodies in COVID-19 patients is higher than that in the control group, and these antibodies last up to 6 months
    .


    Compared with the control group, it was also found that the autoantibodies of non-new coronavirus infections were more diverse.


    The research team also found that from the blood, patients with severe COVID-19 are more likely to have autoantibodies
    .

    Professor Richter explained, "The antibodies we found are similar to those that cause multiple autoimmune diseases of the skin, muscle, and heart
    .


    "

    She said, “We don’t know whether these autoantibodies actually cause symptoms in patients, or whether this is a common phenomenon after infection, or just after COVID-19
    .


    These problems will be in our next research.


    Professor David Cameron Wraith, one of the authors of the paper and Director of the Institute of Immunology and Immunotherapy at the University of Birmingham, added, “In this detailed study of a series of different tissues, we have shown for the first time that COVID-19 infection is associated with selective autoantibodies.
    It is relevant
    .
    ” He believes that more research is needed to determine whether these antibodies will cause the long-term consequences of SARS-CoV-2 infection, so that targeted treatment can be carried out
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.